Form 4: Vera Therapeutics Director, Kimball Hall, Reports Stock Option Grant

Director Kimball Hall of Vera Therapeutics, Inc. reports the acquisition of stock options.

Summary

• On May 15, 2024, Kimball Hall, a director of Vera Therapeutics, Inc., was granted stock options to purchase 14,000 shares of Class A Common Stock.
• The exercise price of the options is $42.69 per share.
• The options vest on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, subject to continuous service.
• The options will fully vest upon a change in control, subject to continuous service through the date of such change in control.
• The options expire on May 14, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard stock option grant to a director, which is generally viewed as a positive sign of aligning interests between management and shareholders. It's a routine event, but contributes to a favorable sentiment.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's success.

Future Outlook

The vesting of the stock options is contingent upon continued service and a potential change in control, suggesting an incentive for the director to remain with the company and contribute to its success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. This grant is consistent with industry practices.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule, contingent on continued service and a change in control, is typical for such grants.
• Comparable companies in the biotech industry, such as BioNTech or Moderna, also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and value creation.

Key Dates